Literature DB >> 11575856

Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin.

R J Robbins1, R M Tuttle, M Sonenberg, A Shaha, R Sharaf, H Robbins, M Fleisher, S M Larson.   

Abstract

Radioiodine ablation (RA) of normal thyroid remnants after thyroidectomy for differentiated thyroid carcinoma improves the sensitivity of subsequent radioiodine scans and serum thyroglobulin measurements for detection of residual thyroid carcinoma. Local cancer recurrences are also lower after RA. One standard preparation for RA involves rendering the patient hypothyroid in order to stimulate endogenous thyrotropin (TSH) secretion and sodium iodide symporter (NIS) activity. An alternative approach is to prescribe thyroxine after thyroidectomy and to stimulate NIS with exogenous recombinant human thyrotropin (rhTSH). This latter approach was used in 10 patients at our medical center. Complete resolution of all visible 131I thyroid bed uptake was achieved in all when follow-up scans were performed 5 to 13 months later. This approach has the potential to successfully ablate thyroid remnants without the need to induce hypothyroidism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11575856     DOI: 10.1089/105072501316973127

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  15 in total

Review 1.  Radioiodine treatment of well-differentiated thyroid cancer.

Authors:  Leonard Wartofsky; Douglas Van Nostrand
Journal:  Endocrine       Date:  2012-06-26       Impact factor: 3.633

Review 2.  ALARA in rhTSH-stimulated post-surgical thyroid remnant ablation: what is the lowest reasonably achievable activity?

Authors:  Daniele Barbaro; Frederik A Verburg; Markus Luster; Christoph Reiners; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-20       Impact factor: 9.236

3.  Examining recombinant human TSH primed ¹³¹I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol.

Authors:  Deepa Rani; Sushma Kaisar; Sushma Awasare; Amit Abhyankar; Sandip Basu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-01       Impact factor: 9.236

4.  What role for recombinant human TSH in the treatment of metastatic thyroid cancer?

Authors:  Paolo Zanotti-Fregonara; Elif Hindié; Marie Elisabeth Toubert; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06       Impact factor: 9.236

5.  Successful use of recombinant human thyrotropin in the therapy of pediatric well-differentiated thyroid cancer.

Authors:  M Ralli; P Cohan; K Lee
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

6.  Comparison of the Influence on the Liver Function Between Thyroid Hormone Withdrawal and rh-TSH Before High-Dose Radioiodine Therapy in Patients with Well-Differentiated Thyroid Cancer.

Authors:  Yeon-Hee Han; Seok Tae Lim; Kuk-No Yun; Sung Kyun Yim; Dong Wook Kim; Hwan-Jeong Jeong; Myung-Hee Sohn
Journal:  Nucl Med Mol Imaging       Date:  2012-04-21

7.  Recombinant TSH-stimulated, radioguided differentiated thyroid carcinoma surgery.

Authors:  Michael E Spieth; Steven B Standiford; Marjorie E Starkman; John Gough
Journal:  Clin Med Res       Date:  2003-01

8.  The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients.

Authors:  Frederik A Verburg; Michael Lassmann; Uwe Mäder; Markus Luster; Christoph Reiners; Heribert Hänscheid
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-06       Impact factor: 9.236

9.  Expanding indications for recombinant human TSH in thyroid cancer.

Authors:  Bryan R Haugen; David S Cooper; Charles H Emerson; Markus Luster; Rui M B Maciel; Rosa P M Biscolla; Ernest L Mazzaferri; Geraldo Medeiros-Neto; Christoph Reiners; Richard J Robbins; Bruce G Robinson; Martin Schlumberger; Shunichi Yamashita; Furio Pacini
Journal:  Thyroid       Date:  2008-07       Impact factor: 6.568

10.  Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer.

Authors:  Bernadette Biondi; Melania Pulcrano; Loredana Pagano; Gaetano Lombardi
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.